Save Big on Coursera Plus. 7,000+ courses at $160 off. Limited Time Only!
Explore groundbreaking research on controlling Helicobacter pylori using engineered probiotics in this 33-minute webinar presented by Christopher Kearney. Delve into the development of highly selective antimicrobial agents against H. pylori, a primary cause of gastric cancer. Learn how Kearney's team fused H. pylori-binding guide peptides with broad-spectrum antimicrobial peptides and engineered the dairy probiotic Lactococcus lactis to secrete these guided antimicrobial peptides (gAMPs). Discover the in vitro results showing the gAMP probiotics' effectiveness against H. pylori while minimizing impact on off-target bacteria. Gain insights into the potential of this innovative approach for preventing gastric cancer and addressing increasing antibiotic resistance. Healthcare professionals can earn PACE credits by watching the webinar and following the provided instructions.